Zimbabwe has rejected a substantial US health deal valued at $367m (£272m) spanning five years over Washington's request for confidential biological samples.
This rejection became public following a internal memorandum dated December was leaked, revealing that Head of State Emmerson Mnangagwa believed the arrangement was "lopsided".
A government spokesman later clarified that the US was demanding access to health data for research and commercial purposes but was unwilling to guarantee the benefits from future treatments.
"We are forced to start the difficult and regrettable process of winding down our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had furnished more than $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for further talks to reach a agreement acceptable to both sides so the country's critical HIV programme can be sustained.
Wider Background
This development comes after a comparable situation in neighbouring Kenya, where a high court blocked a related health funding agreement following legal challenges were filed about the security of Kenyans' medical information.
Since returning to office last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
The agency had administered aid for the American government, but Trump stated its expenditure was "wasteful" and his government was seeking direct bilateral agreements to enhance transparency and accountability.
According to reports, Sixteen African countries have to date agreed to similar health pacts, representing more than $18.3bn in committed funds.
Specifics of the Declined Deal
The money for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation could have provided significant benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving HIV treatment through American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data indefinitely, with no corresponding guarantee of benefiting from any medical innovations – such as new medicines or tests – that could result from that shared data," his statement read.
"In essence, our country would provide the raw materials for medical research without any assurance that the end products would be accessible to our people if a new disease outbreak arise."
Sovereignty and Global Health
He also noted that the US's withdrawal from the global health body and its pursuit of one-on-one deals were disrupting frameworks previously set up via the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system created to manage potential pandemics.
"This mechanism is intended to guarantee that when a nation contributes its data, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
The government's concerns over the US deal "must not be interpreted as anti-American sentiment," he added.
"We welcome continued dialogue with our US partners on how subsequent collaboration could be designed in a way that respects the sovereignty and dignity of each country."
Medical Community Response
A leading public health body said it understood the official position, but suggested that negotiations should continue considering much of the nation's Aids initiatives were funded by foreign aid.
"Where specific concerns arise, including those relating to data governance or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," it added.
The situation highlights the continuing challenges between accepting vital foreign assistance and protecting local interests in an increasingly data-driven world.